Micronoma Wins Bio-IT World Innovative Practices Award
Micronoma, the first cancer detection biotech company to diagnose cancer at an early stage with microbiome-driven liquid biopsy technology, announces that they are the recipient of the Bio-IT World Innovative Practices Award. This elite awards program highlights outstanding examples of how technology innovations and strategic initiatives can advance life sciences research, from basic biomedical research to drug development and beyond.
Micronoma’s microbiome-driven liquid biopsy method uses machine learning to examine thousands of microbiome plasma features to discover, validate, and translate microbial-derived biomarkers into an early cancer detection method. The award from Bio-IT World recognizes that this process is designed to improve the chances of survival of cancer patients by discovering the disease in its earliest stages, including at stage I of the disease, when tumor size is still at its smallest.
“We are honored to receive the Bio-IT World Innovative Practices Award and to be in such great company with our fellow awardees,” said Sandrine Miller-Montgomery, CEO of Micronoma. “This recognition from Bio-IT World adds to an incredible year of discovery and collaboration for Micronoma, and gives even more energy to our team to continue to work hard and fast to save lives.”
Bio-IT World explained that the 2021 awards, which recognize work completed during 2020, are particularly noteworthy. “This has been a uniquely demanding season for the industry, but once again the Bio-IT World community has excelled and delivered innovation and solutions to serve both researchers and patients,” said Allison Proffitt, Bio-IT World editorial director.
Grand prize awards were granted last week to Micronoma and two other winners including Regeneron Pharmaceuticals and Duke Cancer Institute with University of California, San Francisco. Micronoma will join these highly talented recipients in presenting its innovative work at the 2021 Bio-IT World Conference & Expo in Boston in September. The event will be held both online and in-person.
Sandrine Miller-Montgomery, Micronoma’s CEO, will present Micronoma Behind the Scenes Science and Technology: Using the Microbiome to Detect Early-Stage Cancer during the Genome Informatics track on Tuesday, Sept. 21, 2021.
To learn more about Micronoma, please visit Micronoma.com.
- Eloxx Pharmaceuticals Announces Final Data Assessment from Phase 2 Combination Clinical Trial of ELX-02 in Class 1 Cystic Fibrosis Patients Read more
- Verge Genomics Announces Positive Safety and Tolerability Data from the Phase 1 Clinical Trial of VRG50635, a Potential Best-in-Class Therapeutic for All Forms of ALS Read more
- DEM BioPharma Appoints Wendy Young, Ph.D., to Scientific Advisory Board Read more
- Confo Therapeutics Enters into Research Collaboration for GPCR-Targeting Antibody Discovery with AbCellera Read more
- Vyriad Announces Expansion of T-Cell Lymphoma Trial at Mayo Clinic Read more